FLT3 and acute myeloid leukemia: In the QuANTUM-First trial, a randomized phase 3 study for newly diagnosed FLT3-ITD positive adult AML on a quizartinib combination, the addition of quizartinib significantly improved EFS and OS, and toxicities were comparable between the two arms [86].